Warfarin Reversal in Intracerebral Hemorrhage with Prosthetic Mitral Valve
For a patient with a prosthetic mitral valve who develops intracerebral hemorrhage on warfarin, use 4-factor prothrombin complex concentrate (PCC) at 25-50 IU/kg based on INR and body weight, NOT fresh frozen plasma (FFP), along with intravenous vitamin K 10 mg. If PCC is unavailable, FFP should be dosed at 10-15 mL/kg 1.
Why PCC Over FFP
The 2022 AHA/ASA guidelines clearly establish that 4-factor PCC is superior to FFP for warfarin-associated intracerebral hemorrhage 2. The INCH trial demonstrated that PCC achieves significantly faster INR correction than FFP infusion, which is critical in this life-threatening scenario. For intracranial bleeding specifically, fixed-dose regimens of 1500 U have been used, though weight-based dosing (25-50 IU/kg) remains the standard approach 2.
Specific Dosing Algorithm
If PCC is Available (Preferred):
- Dose: 25-50 IU/kg based on presenting INR and body weight
- Higher end (50 IU/kg) for INR ≥4.0
- Lower end (25 IU/kg) for INR 2.0-3.9
- Plus: Vitamin K 10 mg IV (mandatory - prevents INR rebound at 12-24 hours) 2
- Recheck INR: 15-60 minutes post-administration, then every 6-8 hours for 24-48 hours 1
If PCC is Unavailable (Second-line):
- FFP dose: 10-15 mL/kg IV 1
- For a 70 kg patient: 700-1050 mL
- For an 80 kg patient: 800-1200 mL
- Plus: Vitamin K 10 mg IV 1
Critical Considerations for Prosthetic Mitral Valve
This patient presents a unique challenge: they have a mechanical mitral valve requiring target INR 2.5-3.5 3, yet now has life-threatening bleeding requiring complete reversal. The prosthetic valve creates high thromboembolic risk once anticoagulation is reversed.
Key management points:
- Reverse anticoagulation completely first - mortality from ICH expansion outweighs short-term thrombotic risk
- Target INR <1.4 for hemorrhage control 1
- Multidisciplinary discussion (neurosurgery, cardiology, hematology) regarding timing of anticoagulation resumption
- Consider heparin bridging once hemorrhage is stable (typically 7-14 days post-bleed, depending on imaging)
Why Vitamin K is Mandatory
Always give vitamin K 10 mg IV regardless of whether you use PCC or FFP 2, 1. Case reports demonstrate that PCC without vitamin K can cause INR rebound at 12-24 hours, with one patient experiencing hematoma enlargement and clinical deterioration 2. Vitamin K provides sustained reversal while PCC/FFP provides immediate correction.
Common Pitfalls
Using FFP when PCC is available: FFP requires large volumes (often >1 liter), takes longer to infuse, and achieves slower INR correction - all disadvantages in ICH 2
Omitting vitamin K: This leads to INR rebound and potential re-bleeding 2
Over-dosing PCC when INR is only mildly elevated: If INR is 1.3-2.0, use lower PCC doses (10-20 IU/kg) to avoid thrombotic complications 2
Not rechecking INR: Must verify reversal at 15-60 minutes and monitor serially. If INR remains ≥1.4 after initial PCC, consider additional FFP 1
Resuming anticoagulation too early: Despite the prosthetic valve, hemorrhage stabilization takes priority. Imaging must confirm stability before restarting anticoagulation
Monitoring Protocol
- Immediate: INR at 15-60 minutes post-reversal
- Serial: INR every 6-8 hours for first 24-48 hours 1
- Imaging: Repeat head CT at 6-24 hours to assess for expansion
- If INR remains elevated (≥1.4) on repeat testing: Give FFP 10-15 mL/kg 1
The 2016 Neurocritical Care Society guidelines provide strong recommendations (moderate quality evidence) for this approach, with the 2022 AHA/ASA guidelines reinforcing PCC superiority over FFP 2, 1.